1. Home
  2. NFE vs GLSI Comparison

NFE vs GLSI Comparison

Compare NFE & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Fortress Energy Inc.

NFE

New Fortress Energy Inc.

HOLD

Current Price

$0.59

Market Cap

324.4M

Sector

Utilities

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$22.03

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFE
GLSI
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.4M
372.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
NFE
GLSI
Price
$0.59
$22.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$7.70
$50.00
AVG Volume (30 Days)
20.3M
131.3K
Earning Date
05-11-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,364,860,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$89.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$7.78
52 Week High
$7.05
$34.10

Technical Indicators

Market Signals
Indicator
NFE
GLSI
Relative Strength Index (RSI) 27.37 41.27
Support Level $0.56 $21.20
Resistance Level $1.38 $30.02
Average True Range (ATR) 0.11 1.87
MACD -0.01 -0.39
Stochastic Oscillator 5.07 15.54

Price Performance

Historical Comparison
NFE
GLSI

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: